Aurinia Pharmaceuticals Inc Ordinary Shares AUPH
i
Market dataready · fetched 2026-11-11T03:54:19.032Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:01.176249742Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T03:54:18.788124+00:00
Aurinia Pharmaceuticals Inc Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 15.45 | 66.6% | 7.5% | |||
| 35Δ | 15.72 | 63.7% | 6.2% | |||
| 40Δ | 15.98 | 60.8% | 5.0% | |||
| 45Δ | 16.09 | 56.7% | 4.5% | |||
| 50Δ | 16.19 | 52.6% | 4.0% | |||
| 55Δ | 16.29 | 48.4% | 3.5% | |||
| 60Δ | 15.90 | 217.6% | 13.0% | 16.39 | 44.3% | 3.0% |
| 65Δ | 15.16 | 213.2% | 10.4% | |||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.45
- IV
- 66.6%
- B/E move
- 7.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.72
- IV
- 63.7%
- B/E move
- 6.2%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.98
- IV
- 60.8%
- B/E move
- 5.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.09
- IV
- 56.7%
- B/E move
- 4.5%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.19
- IV
- 52.6%
- B/E move
- 4.0%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.29
- IV
- 48.4%
- B/E move
- 3.5%
60Δ
- Pseudo strike
- 15.90
- IV
- 217.6%
- B/E move
- 13.0%
- Pseudo strike
- 16.39
- IV
- 44.3%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- 15.16
- IV
- 213.2%
- B/E move
- 10.4%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 57.16% | |
| 57.63% | |
| 57.06% | |
| 46.37% | |
| 58.66% | |
| 46.88% | |
| 46.39% | |
| 59.74% | |
| 54.15% | |
| 40.98% |
Biotechnology
AURA
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The…
More →AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United…
More →AVBP
ArriVent BioPharma, Inc. (AVBP) is a dynamic biopharmaceutical company dedicated to developing pioneering therapies that address critical unmet needs in oncology and autoimmune…
More →AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral…
More →AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe respiratory diseases, with its lead candidate, AV-101,…
More →AVTX
Description unavailable
More →